Gilead loss of generic HIV drug battle a boost for gay community - (The Irish Times via NewsPoints Desk)

  • Generic versions of Gilead Sciences' HIV drug Truvada could soon become available in Ireland after the drugmaker lost a legal battle seeking to block their market entry, The Irish Times reported.

  • In the case, Gilead asked Ireland's High Court to bar Teva and Mylan from launching generic versions of Truvada, which lost patent protection in July, based on a supplementary protection certificate (SPC) protecting market exclusivity until 2020.

  • The court rejected Gilead's request for a provisional injunction, which would have blocked generic competition until a full trial.

  • Ireland's Health Service Executive currently spends about 24 million euros on the drug annually for both HIV treatment and pre-exposure prophylaxis.

  • Mylan and Teva are also challenging SPCs for Truvada in other countries in Europe, including Germany and Spain.

  • FirstWord Reports: Providing insight, analysis and expert opinion on important Pharma trends and challenging issues <Click here>

To read more NewsPoints articles, click here.